22 November 2021
The first of three webinars from A.S.K, our new medical education programme, took place this month and discussed adapting to the use of biosimilar medications in the treatment of patients and the factors to consider when adding a biosimilar medication to the formulary.
The first A.S.K webinar, ‘Adapting to a changing landscape: switching to oncology biosimilars’, featured discussion from our expert faculty, Emma Foreman, Phillippe Arnaud and Glenn Myers.
A.S.K.– Attitude, Skills and Knowledge in Oncology Biosimilars, is a new medical education programme aimed at the hospital-based pharmacist community to provide education that will increase their knowledge and confidence in using biosimilar medications when treating oncology patients.
A further two case study webinars will be taking place on the 24th and 30th November 2021, covering the topics of patient engagement and pharmacovigilance when implementing biosimilar medications. Alongside the webinars, an educational handbook has been developed and is available to download on the website.
In 2022 the website will also feature 10 learning chapters, a library of 30 abstracts and local guideline summary documents, with all resources translated into French, German, Italian, Spanish and Japanese. This programme specifically targets clinicians in Western Europe, Canada and Japan. Other members of the multidisciplinary team are also encouraged to make use of these resources.
The programme’s resources will be marketed to our hospital-based pharmacist community, including via our media brands Hospital Pharmacy Europe and Hospital Healthcare Europe.